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Although an early invasive strategy (angiography and percutaneous coronary intervention) is
the convention in acute coronary syndrome (ACS)/non–ST-segment elevation myocardial
infarction (MI) in the U.S., a conservative pharmacologic approach is common in other
countries. Trial evidence has demonstrated a modest benefit with an angiographically guided
approach; but patients having negative troponin values or who were receiving aspirin showed
little or no benefit, and those without ST-segment changes had slightly worse outcomes.
Limitations of angiography are clinically important. Identification of hemodynamically
significant stenoses may be confounded by coronary remodeling. Also, most plaques,
particularly those responsible for acute events, are extraluminal. Assessment of the luminal
diameter of a lesion, which requires comparison with a normal reference segment, may be
impossible because of the diffuse nature of the disease. Percutaneous coronary intervention
after plaque rupture may itself cause embolization and no-reflow phenomena, leading to
severe complications. In addition, most ruptures may be clinically silent. Evidence of a
systemic inflammatory component suggests that ACS patients are at risk for plaque rupture
at multiple sites. The inability of angiography to depict the true extent of atherosclerosis is
supported by necropsy and transplant donor studies. A metabolic approach to this systemic
disease is the only strategy designed to influence the behavior of both the small number of
angiographically visible lesions and the large number of occult plaques. Statins and other
agents decrease the incidence of death and MI by stabilizing atherosclerotic plaques
throughout the coronary bed, reducing inflammation, collagen degradation, tissue factor
expression, and vasomotor tone. (J Am Coll Cardiol 2003;41:103S–112S) © 2003 by the
American College of Cardiology Foundation
Hospital admissions for acute coronary syndrome (ACS) or
non–ST-segment elevation myocardial infarction (NSTEMI)
occur in more than 1.4 million patients annually in the U.S.
(1996 data) (1), but the optimal approach to its manage-
ment remains controversial. In most American tertiary care
centers, ACS patients are managed using an aggressive early
invasive strategy, defined as angiography and percutaneous
coronary intervention (PCI) within a few hours to a few
days after presentation. However, most practice patterns
and guidelines outside the U.S. promote an initial early
conservative approach that uses anti-ischemic, anti-platelet,
and anti-thrombotic drug therapy while they reserve urgent
angiography and intervention for high-risk patients or those
with refractory symptoms. With this approach, clinically
stable patients undergo functional testing to stratify them
for elective coronary angiography.
Advances in medical and interventional care have made
comparison studies of conservative versus aggressive strate-
gies difficult to interpret (2–8). Key advances in PCI include
stenting with adjunctive use of glycoprotein (GP) IIb/IIIa
inhibitors. Advances in medical therapy include GP IIb/IIIa
inhibitors and/or clopidogrel, low-molecular-weight hepa-
rins, and aggressive use of lipid-lowering agents. Few trials
have made comparisons between angiographically guided
management and optimal medical therapy; however, a
review of existing trials and an understanding of the
pathophysiology of ACS provide a reasonable basis for
making decisions. This review provides the rationale for
approaching ACS as a systemic disease, rather than focusing
on identification and interventional treatment of the focal
stenosis.
CLASSICAL INVASIVE VERSUS CONSERVATIVE TRIALS
The scientific case for an angiographically guided approach
to ACS is not particularly well supported by traditional
clinical trials, despite its popularity in the U.S. Before the
development of stenting and GP IIb/IIIa inhibitors, the
Thrombolysis In Myocardial Infarction (TIMI) IIIB study
randomized 1,473 patients with unstable angina or
NSTEMI and compared tissue plasminogen activator with
placebo, and an early invasive with an early conservative
strategy (9). Patients received what was then considered
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optimal medical therapy, including a beta-blocker, a short-
acting calcium channel antagonist, nitrates, unfractionated
heparin, and aspirin. In the tissue plasminogen activator
versus placebo comparison, there were no significant differ-
ences in the six-week incidence of death, MI, or failure of
initial therapy. Similarly, no differences were found between
the invasive-versus-conservative arms in the six-week inci-
dence of death, MI, or a poor performance on an exercise
test (symptom-limited). However, patients treated with an
aggressive strategy had significantly less recurrent ischemia
requiring repeat hospitalization and needed fewer anti-
anginal medications.
Conversely, the Veterans Affairs Non–Q-Wave Infarc-
tion Strategies in-Hospital (VANQWISH) trial suggested
that an aggressive approach might actually worsen out-
comes. This study randomized 920 NSTEMI patients to an
early invasive or early conservative strategy (10). At hospital
discharge, the invasive-strategy arm was associated with
significantly higher rates of death (26% vs. 12%; p  0.004)
or non-fatal MI (15% vs. 4.9%; p  0.007). These differ-
ences persisted to one month and one year.
The Fragmin and Fast Revascularization during InSta-
bility in Coronary artery disease (FRISC) II trial random-
ized 2,457 chest-pain patients with electrocardiographic
changes or positive enzymes to the low-molecular-weight
heparin, dalteparin, or placebo with either an invasive or
conservative strategy (11). Stents were utilized in about
two-thirds of PCI patients in both the invasive and conser-
vative arms. At six months, there were no significant
differences between dalteparin- and placebo-treated pa-
tients. However, death or MI was more common in the
conservative than in the invasive group (12.1% vs. 9.4%; p
0.03). Angina severity and need for re-admission were also
less common in the invasive arm.
CONTEMPORARY TRIALS
TACTICS. The Treat angina with Aggrastat and deter-
mine Cost of Therapy with an Invasive or Conservative
Strategy (TACTICS) TIMI-18 study was organized to try
to confirm whether an invasive approach was superior to a
conservative strategy using contemporary pharmacotherapy
and intervention techniques (12). All 2,220 NSTEMI/ACS
patients received aspirin, heparin, and the GP IIb/IIIa
inhibitor, tirofiban. In the invasive arm, angiography was
performed 4 to 48 h after randomization. Revascularization
was performed in 60% of patients in the invasive arm and
36% in the conservative arm, with at least one stent
deployed in approximately 85% of PCIs. Medications in-
cluded beta-blockers (82%), nitrates (94%), and lipid-
lowering agents (52%).
The TACTICS TIMI-18 was the first contemporary
trial to demonstrate a modest benefit from an
angiographically-guided approach. The triple end point of
death, non-fatal MI, or re-admission for ischemia at six
months was significantly lower in the aggressive than in the
conservative arm (15.9% vs. 19.4%; p  0.025). The double
end point of death or MI was also lower, but only margin-
ally, in the invasive arm (7.3% vs. 9.5%; p  0.05).
Surprisingly, however, the two-thirds of patients taking
prophylactic aspirin and the 59% of troponin T-negative
patients (0.1 ng/ml) showed little or no benefit from early
invasive treatment. Furthermore, the 62% of subjects with-
out ST-segment changes showed a slightly worse primary
end point with early invasive strategy. Only the highest-risk
ACS patients appeared to benefit, even with the use of GP
IIb/IIIa inhibitor and stenting.
Limitations of interventional strategies. STENOSIS EVAL-
UATION USING ANGIOGRAPHY. Although coronary angiog-
raphy is the gold standard for defining coronary anatomy,
radiographic imaging depicts only a rather poor representa-
tion of cross-sectional coronary anatomy from a simple
planar silhouette or luminogram of the contrast-filled lu-
men. Angiography is confounded by observer variability,
with differences in the estimation of stenosis severity ap-
proaching 50% (13,14). Also, functional testing often re-
veals discordance between the severity of angiographic
lesions and physiologic effects (15,16). Necropsy studies and
intravascular ultrasound (IVUS) demonstrate that coronary
lesions, particularly after plaque rupture, are complex, with
distorted luminal shapes (17) that are difficult to assess using
a planar angiographic silhouette (Fig. 1).
Nevertheless, operators usually choose not to treat steno-
ses that do not appear hemodynamically significant, reserv-
ing intervention and PCI for visually severe lesions. How-
ever, intervention after plaque rupture and thrombosis is not
without hazard. Embolization and no-reflow phenomena
after successful angiographic intervention may lead to com-
plications resulting in myocardial necrosis, unquestionably
making some patients worse.
Trial data provide ample evidence that the limitations of
angiography result in inappropriate treatment of lesions,
resulting in adverse outcomes. Twice as many trial patients
have undergone revascularization in early-invasive than in
ischemia-guided arms. As mentioned above, TACTICS
patients without ST-segment changes actually fared worse
with an early invasive approach, despite receiving upstream
GP IIb/IIIa inhibitors. Also, patients in the VANQWISH
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
CAD  coronary artery disease
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infarction
PCI  percutaneous coronary intervention
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trial who were treated aggressively had a threefold increase
in non-fatal MIs.
THE DIFFUSE NATURE OF THE DISEASE. Angiography may
also underestimate the extent of atherosclerosis (18,19).
Both imaging and necropsy studies demonstrate that coro-
nary artery disease (CAD) is rarely focal and typically
involves a large portion of the arterial tree at the time of
diagnosis (20,21). Indeed, with the appearance of the first
Figure 2. Coronary remodeling concealing extensive disease. Intravascular ultrasound cross-sections from four sites (A, B, C, and D) are shown. At each
site, there is extensive atherosclerosis, but without luminal encroachment. Comparing lumen size from the least diseased segment, D, to the most diseased
segments, A and B, there is no change in lumen size.
Figure 1. Angiogram of complex lesion of right coronary artery. Several features make this artery difficult to evaluate by angiography. The lesion is complex with
a bulbous projection that is difficult to quantitate. In addition, there is uncertainty regarding which segment to consider normal for comparative purposes.
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luminal irregularity, at least 80% of the coronary tree is
already atherosclerotic.
Angiographic assessment is confounded by a phenome-
non known as coronary remodeling (22), which consists of
outward displacement of the external elastic membrane
(EEM) in atherosclerotic segments, opposing luminal en-
croachment and concealing the presence of disease (Fig. 2).
Lesion assessment requires a comparison of the luminal
diameter with an adjacent, normal reference segment. Be-
cause coronary atherosclerosis is usually diffuse, however,
there may be no truly normal segment from which to
determine diameter reduction. In the presence of diffuse
disease, percent stenosis will always underestimate the
severity of the disease. In extreme examples, the entire vessel
may be symmetrically narrowed, appearing as a small artery
with minimal irregularities (Fig. 3). Therefore, exclusive
focus on a culprit stenosis ignores the diffuse nature of the
atherosclerotic disease process.
IMPORTANCE OF THE NON-STENOTIC LESION. Abundant
evidence demonstrates that high-grade stenoses (70%
obstruction) are rarely the source of ACS and that coronary
occlusion and MI evolve most frequently from plaques that
are only mildly to moderately obstructive on angiography
(23). In clinical trials, about 20% of ACS patients under-
going early angiography exhibit no hemodynamically sig-
nificant stenosis (24). Furthermore, because intra-lesional
thrombus contributes to the severity of stenosis, delayed
angiography often shows a less severe stenosis after an
underlying thrombus has been resolved. In most clinical
trials, a delay in angiography resulted in a reduction in the
number of patients who underwent PCI.
Figure 3. Diffuse disease masquerading as a normal artery. Two sites, A and B, are shown by intravascular ultrasound. At both sites, a diffuse, concentric
and symmetrical plaque involves the entire vessel circumference, giving the false appearance of a normal artery.
Figure 4. Positive remodeling in a ruptured plaque. A ruptured plaque (right) is shown, along with a relatively normal adjacent reference segment (left).
In the right panel, an interruption of the fibrous cap can be seen with exposure of the underlying lipid core. Compared with the normal reference segment,
the external elastic membrane (EEM) area is considerably larger in the segment with plaque rupture than in the adjacent normal reference segment.
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The relationship between minimally obstructive stenoses
and MI initially suggested that ACS evolves from the
rupture of small, early atheromatous plaques. Recently,
evidence from IVUS has offered a more complete explana-
tion in stable versus unstable syndromes (25). We per-
formed IVUS before coronary intervention in unstable (n 
85) and stable (n  46) angina patients. A remodeling ratio
(RR) was defined as the ratio of the EEM area at the lesion
to that at the proximal reference site. Positive remodeling
was defined as an RR 1.05 and negative remodeling as an
RR 0.95. Surprisingly, plaque area (13.9 vs. 11.1 mm2; p
 0.005), EEM area (16.1 vs. 13.0 mm2; p  0.004), and
the RR (1.06 vs. 0.94 mm2; p  0.008) were significantly
greater at culprit lesions in patients with unstable syn-
dromes. Positive remodeling was more frequent in unstable
than in stable lesions (51.8% vs. 19.6%; p  0.001) (Fig. 4).
Inflammation may be a common pathophysiologic link
underlying the association between plaque vulnerability and
remodeling. An IVUS and histologic study of the human
femoral arteries showed an association between histologic
markers associated with plaque inflammation and positive
arterial remodeling (26). Comparative analysis of the pre-
atherectomy ultrasound images and histology of the plaque
tissue demonstrated an association between positive remod-
eling and intense stromolysin staining (an enzyme associ-
ated with degradation of the fibrous cap) (27), suggesting
that degradation of the extracellular matrix plays a role in
arterial remodeling.
Because bulky, non-stenotic lesions cause many, if not
most, infarctions, the most severely stenotic lesion may not
invariably be the culprit. Numerous ACS/NSTEMI pa-
tients have been identified in whom a comparatively minor
stenotic lesion, distant from a ruptured plaque, was the
apparent culprit lesion (Fig. 5). The morphologic charac-
teristics of the vulnerable lesion are clearly more important
in plaque vulnerability than percent stenosis. Plaque echolu-
cency, which represents the lipid content of plaques, and a
thin fibrous cap have been associated with ACS (28). Stable
plaques characteristically have thick fibrous caps and small
lipid cores. Fibrotic changes and vessel shrinkage, while
causing more severe luminal stenosis, may render lesions
more resistant to rupture.
Multiplicity of vulnerable plaques. Angioscopic and an-
giographic studies have identified lesions with characteris-
tics associated with plaque vulnerability at sites other than
the culprit lesion in ACS patients (29,30). Although rupture
of a vulnerable atheroma is the major cause of ACS/
NSTEMI, recent reports suggest that most ruptures are
clinically silent and only occasionally cause acute symptoms
(31). Presumably, after a rupture, the local balance between
thrombosis and spontaneous thrombolysis prevents vessel
occlusion. Recent evidence of a systemic inflammatory
component also suggests that multiple sites are at risk for
plaque rupture (32).
We hypothesized that ACS patients would exhibit more
extensive plaque vulnerability, manifested by lesion ulcer-
ation, at sites other than the culprit lesion. We therefore
examined the prevalence of ulcerated atherosclerotic lesions
in vessel segments adjacent to culprit lesions in patients with
stable versus those with unstable syndromes. Post-
interventional IVUS examinations were performed in pa-
tients treated with emergent stenting for acute MI. Control
Figure 5. The non-stenotic lesion as culprit. A patient with unstable angina was examined by coronary angiography and intravascular ultrasound (IVUS).
The right coronary angiogram (far left, top panel) shows a right coronary artery lesion that was subsequently stented (far left, bottom panel). The IVUS
examination of the mildly diseased left circumflex (middle panel) reveals a site (black arrow) that by IVUS (far right panel) shows a fresh plaque rupture
(cavity from 12 to 2 o’clock).
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patients were treated with elective stenting for either stable
or unstable angina. Plaque ulceration distant from the
infarct site was significantly more prevalent in the post-MI
than the angina group (19% vs. 4%) (Schoenhagen P, et al.,
unpublished data).
These observations may explain the extraordinary differ-
ence in prognosis between patients with ACS/NSTEMI
and chronic stable angina patients. Annual rates of death
and MI average about 2% in chronic stable angina. The
TACTICS trial, however, demonstrated a combined risk of
death, non-fatal MI, and rehospitalization of approximately
16% at six months in ACS patients. Although the angio-
graphically guided approach to ACS assumes that the focal
lesion responsible for the unstable presentation can be
readily identified and treated, this assumption is not invari-
ably true.
Early onset of the systemic process. Although CAD
patients typically become symptomatic after age 40, athero-
sclerotic changes in the vessel wall begin early in life
(33–35). Gross inspection of coronaries of the American
soldiers killed in the Korean and Vietnam wars demon-
strated atherosclerosis in 77% and 45% of autopsies, respec-
tively. In the Bogalusa Heart Study, the prevalence of CAD
in 15-year-old children was 8%, reaching 69% in adults 26
to 40 years old.
Recently, we used IVUS in 262 heart transplant recipi-
ents to determine the presence, extent, and distribution of
atherosclerosis in donor coronaries within weeks of trans-
plantation (36). This method was designed to characterize
the early atherosclerotic process, reflecting the fact that most
donors are relatively young (Fig. 6). Donor atherosclerotic
lesions were present in 136 patients, or 51.9% (Fig. 7). The
prevalence of atherosclerosis varied from 17% in individuals
20 years old to 85% in subjects 50 years old. Because
remodeling is evident in many early lesions, the lumen is
usually preserved at first. Few lesions were detected by angiog-
raphy, with stenoses identified in only 8% of patients. No
abnormal angiograms were found in patients 30 years old,
yet 28% of them had ultrasound evidence of atherosclerosis.
If young healthy transplant donors have extensive athero-
sclerosis, it is not difficult to imagine the plaque burden in
patients with an ACS. Accordingly, it seems unrealistic to
expect the placement of a stent in a culprit lesion to
significantly alter a process that began decades earlier and
Figure 6. Coronary disease in a 33-year-old transplant donor. The left anterior descending (left) and circumflex (right) show significant atherosclerosis in
a previously asymptomatic young man who was a transplant donor after a motor vehicle accident.
Figure 7. Prevalence of coronary disease in transplant donors. These data
demonstrate an aggressive increase in the likelihood of an atheroma of at
least 0.5 mm in thickness in individuals as young as 13 years of age. yrs. 
years. Tuzcu EM, Kapadia SR, Tutar E, et al High prevalence of coronary
atherosclerosis in asymptomatic teenagers and young adults: evidence from
intravascular ultrasound. Circulation 2001;103:2705–10. Adapted with
permission from Lippincott, Williams, and Wilkins.
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involves most of the coronary arterial tree. A metabolic
approach is the only strategy able to affect the behavior of
both the small number of angiographically visible lesions
and the large number of occult, extraluminal plaques that
will ultimately result in future coronary events.
Plaque progression and vulnerability. The formation of
atherosclerotic lesions is initiated by the recruitment of
mononuclear leukocytes to the intima by adhesion mole-
cules expressed on the surface of vascular endothelial cells
(37). Chemoattractants facilitate entry into the intima,
where macrophages accumulate lipid to become foam cells.
A large, often eccentric, lipid pool forms, separated from the
lumen by a fibrous cap (38). Positive remodeling, the
outward expansion of the vessel at the lesion site, allows
plaque accumulation without lumen obstruction (22). The
accumulation of inflammatory cells and the changes in
extracellular matrix macromolecules contribute to the
changes in vascular morphology (39,40). These atheromata
may remain silent for decades (41). Incompletely under-
stood triggers may then initiate changes that lead to rupture
and an ACS (42).
The border between the fibrous cap and normal vessel
wall at the edge of a large lipid core (the so-called “shoulder
area”) is particularly prone to rupture (43) (Fig. 8). The
tensile strength of the fibrous cap depends on a balance
between collagen biosynthesis by smooth muscle cells and
collagen degradation by members of several proteinase
families and their endogenous inhibitors (44,45). The se-
cretion of these proteinases is induced by the accumulation
and activation of macrophages and other inflammatory cells
(46). Matrix-metalloproteinases (MMPs) play a central role
in the degradation of the extracellular matrix of the fibrous
cap (47).
When a plaque ruptures, platelets that accumulate on
exposed plaque increase expression of the GP IIb/IIIa
receptor complex, initiating further platelet aggregation and
fibrin deposition and eventually forming a luminal throm-
bus (48). The eventual thrombus size is determined by the
balance between the prothrombotic milieu and local, intrin-
sic thrombolytic activity. Some of these episodes of plaque
rupture are clinically symptomatic, but most are silent.
Further plaque development is characterized by fibrosis,
leading to a thick fibrous cap and a small lipid core (45)
(Fig. 9). Fibrotic changes and vessel shrinkage, while
causing more severe luminal stenosis, render lesions more
resistant to rupture and can be regarded as part of a healing
process. The progression of lesions through repeated cycles
of vulnerability and rupture, with subsequent lesion stabili-
zation, is probably a common pattern.
If future events are to be avoided, atheroma formation,
inflammation and rupture must be prevented. There is
already evidence that lipid-lowering therapies can interrupt
the atherosclerotic disease process, significantly influencing
outcome in ACS patients.
Lipid-lowering and plaque progression. Percutaneous
coronary intervention reduces the severity of angina by
improving coronary blood flow in the target vessel. How-
ever, the effect of lipid-lowering agents on cardiac events is
far greater than their effect on the severity of angiographic
stenosis (49,50). Imaging studies have confirmed in vivo
Figure 8. Plaque rupture by intravascular ultrasound (IVUS). Two adjacent sites in the coronary artery of a patient with an acute myocardial infarction are
shown. In the right panel, the IVUS catheter is in a small lumen separated by a fibrous cap from a large lipid core. In this example, the lipid core is no
longer present, and there is blood flow through the center of this atherosclerotic plaque. In the left panel, rupture of the fibrous cap can be seen at
approximately 12 o’clock, and the underlying lipid core has apparently escaped after plaque rupture.
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that statin therapy reduces plaque size and may change
plaque composition without substantial changes in luminal
area (20,51), suggesting that lipid-lowering therapy may
regress or stabilize lipid-rich lesions. Unlike PCI, systemic
therapies treat all of the potentially vulnerable plaques in the
coronary arteries, not simply the focal lesion responsible for
the ACS. Statins do not substantially change luminal area,
but they decrease the incidence of death and MI by
stabilizing atherosclerotic plaques throughout the coronary
bed.
A small IVUS study examined the progression of athero-
sclerosis after three years of treatment with pravastatin or
diet in mildly diseased coronaries (52). During follow-up,
plaque area increased by 41% in the control group but
decreased by 7% in the treatment group. In a more recent
serial IVUS study, patients (n  131) were randomized to
treatment with high-dose atorvastatin or “usual care,” which
could include statin therapy (51). After 12 months, mean
low-density lipoprotein-cholesterol was reduced from 155
to 86 mg/dl in the atorvastatin group and from 166 to 140
mg/dl in the usual-care group. Mean absolute plaque
volume showed a larger but insignificant increase in the
usual-care group compared with the atorvastatin group (9.6
mm3 vs. 1.2  30.4 mm3). Plaque echogenicity increased to
a larger extent in the atorvastatin group than in the
usual-care group.
Larger, ongoing serial regression-progression trials in-
clude the Reversal of Atherosclerosis with Aggressive Lipid
lowering (REVERSAL) trial, which is comparing two
lipid-lowering regimens, and the Norvasc for Regression of
Manifest Atherosclerotic Lesions (NORMALISE) trial,
which is evaluating amlodipine versus enalapril, or placebo
(50). The primary end point of these trials is plaque burden,
not lumen size. Although the relationship between changes
in plaque burden and clinical events remains to be estab-
lished, the potential of anti-atherosclerotic therapies to limit
plaque growth or induce regression is very promising.
Lipid lowering and plaque stability The Myocardial Isch-
emia Reduction with Aggressive Cholesterol Lowering
(MIRACL) trial randomized 3,086 patients with ACS or
NSTEMI to atorvastatin (80 mg/day) or placebo initiated
24 to 96 h after hospital admission. In the atorvastatin
group, mean low-density lipoprotein cholesterol declined
from 124 mg/dl (3.2 mmol/l) to 72 mg/dl (1.9 mmol/l). The
primary end point (16 weeks) was death, non-fatal acute
MI, cardiac arrest with resuscitation, or recurrent symptom-
atic myocardial ischemia with objective evidence and requir-
ing emergency rehospitalization. A primary end point event
occurred in 228 patients (14.8%) in the atorvastatin group
and 269 patients (17.4%) in the placebo group (relative risk,
0.84; 95% confidence interval, 0.70 to 1.00; p  0.048).
There were fewer strokes in the atorvastatin group than in
the placebo group (12 vs. 24 events; p  0.045).
How might anti-atherosclerotic therapy improve early
outcomes in ACS? Benefits are probably not derived strictly
through regression of fixed stenoses (49). Libby and col-
leagues has demonstrated that a low-fat diet or treatment
with lipid-lowering agents can reduce macrophage numbers
and MMPs and increase collagen contents, thereby limiting
oxidized low-density lipoprotein in the vessel wall and
limiting the transformation of plaques to an unstable mor-
phology (53–55). In experimental animals, a low-cholesterol
Figure 9. Stable and vulnerable coronary atheromata. In the left panel, a lesion with a thick fibrous core and small lipid core is illustrated. The right panel
shows a lesion in a different patient with a thin fibrous cap and a large lipid core. The left hand plaque might be termed “stable” and the right hand plaque
“vulnerable” based on pathological criteria.
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diet reduced both the amount and activity of tissue factor,
the most thrombogenic component of plaques. Lowering
lipids also reduces expression of noxious inflammatory
stimuli (i.e., interferon, tumor necrosis factor) that have the
potential to destabilize the atheroma and influence vasomo-
tor tone through effects on nitric oxide synthase (55). In
experimental animals, statins reduce macrophage accumu-
lation, inflammation, and proteolytic activity (54). Similarly,
a study of primates treated with statins found decreased
coronary vasomotor tone and reduced numbers of intimal
and medial macrophages (54).
The profound effects of anti-atherosclerotic therapies on
plaque morphology and behavior render such treatments
ideal for ACS patients. Reductions in atheroma inflamma-
tion, collagen degradation, tissue factor expression, and
vasomotor tone have the potential to treat not only a single
lesion, as in PCI, but also the entire systemic disease
process. Entirely new classes of atherosclerosis-modulating
therapies are under development, including agonists of the
peroxisome proliferator-activated receptor (PPAR) system,
including PPAR alpha agents that modulate lipid metabo-
lism and PPAR gamma agonists that modulate both lipid
and glucose metabolism. New anti-atherosclerotic therapies
include inhibitors of acyl-CoA:cholesterol O-acyltransferase
that prevent accumulation of cholesterol ester in the mac-
rophage, and inhibitors of cholesterol ester transfer protein
that can raise high-density lipoprotein cholesterol by 50% or
more.
Ultimately, medical therapy and PCI should be consid-
ered as complementary rather than opposing strategies in
the treatment and management of atherosclerosis and ACS.
Patients are likely to benefit to the greatest extent from
intervention when it is performed in combination with
aggressive medical therapy.
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